Usana Health Sciences Inc (USNA) valuation
Usana Health Sciences P/E ratio history
Usana Health Sciences has no meaningful price to earnings ratio at the last close, which happens when earnings over the last twelve months are negative or close to zero. At its last 10 fiscal year ends its P/E ranged from 13.2 (year to Jan 2021) to 33.5 (year to Jan 2026), with a median of 17.0.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Jan 3, 2026 | $19.44 | $0.58 | 33.5 | 6.6 |
| Dec 28, 2024 | $35.69 | $2.19 | 16.3 | 14.4 |
| Dec 30, 2023 | $53.60 | $3.30 | 16.2 | — |
| Dec 31, 2022 | $53.20 | $3.59 | 14.8 | 16.0 |
| Jan 1, 2022 | $101.20 | $5.73 | 17.7 | — |
| Jan 2, 2021 | $77.10 | $5.86 | 13.2 | — |
| Dec 28, 2019 | $80.00 | $4.42 | 18.1 | — |
| Dec 29, 2018 | $114.96 | $5.11 | 22.5 | — |
| Dec 30, 2017 | $74.05 | $2.52 | 29.4 | — |
| Dec 31, 2016 | $61.20 | $3.99 | 15.3 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Usana Health Sciences valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Usana Health SciencesUSNA | $264M | — | 11.2 | 0.3 |
| AlicoALCO | $277M | 178.1 | — | 16.2 |
| Nu Skin EnterprisesNUS | $226M | — | 4.7 | 0.2 |
| BrcBRCC | $314M | — | 51.5 | 0.7 |
| Natures Sunshine ProductsNATR | $215M | 12.1 | 10.6 | 0.4 |
| Lifeway FoodsLWAY | $350M | 33.2 | 24.8 | 1.4 |
| LimoneiraLMNR | $194M | — | 61.4 | 1.5 |
| Mgp IngredientsMGPI | $367M | — | 9.1 | 0.8 |
| B And G FoodsBGS | $188M | — | 4.3 | 0.1 |
| Peer median | 33.2 | 10.6 | 0.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: USNA financials · USNA returns
No forecast, no recommendation. This page describes Usana Health Sciences Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.